Felix Von Coerper

Biography

Mr. Von Coerper began serving as a director of Amylyx in 2016. Mr. Von Coerper currently is the managing partner of the ALS Investment Fund, a venture capital fund based in the Netherlands exclusively focused on investment in promising ALS technologies. He has over 19 years experience in early stage venture management & finance. He founded a served as CEO of Elana and was CEO of MySample BV. He received his Masters in Economics from the Erasmus University Rotterdam. 

Research Interest

mylyx is developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that targets the neuroinflammation and nerve cell death that characterize these disorders. The company’s therapeutic, AMX0035, is a proprietary combination of existing compounds that Amylyx has demonstrated have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models.